Zobrazeno 1 - 10
of 13
pro vyhledávání: '"James E. Glassbrook"'
Autor:
Justin B. Hackett, James E. Glassbrook, Maria C. Muñiz, Madeline Bross, Abigail Fielder, Gregory Dyson, Nasrin Movahhedin, Jennifer McCasland, Claire McCarthy-Leo, Heather M. Gibson
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Immune checkpoint inhibitors (ICI) have improved outcomes for a variety of malignancies; however, many patients fail to benefit. While tumor-intrinsic mechanisms are likely involved in therapy resistance, it is unclear to what extent host genetic bac
Externí odkaz:
https://doaj.org/article/c305df24d9bf42e991b7eaf907259bb5
Autor:
Nerissa T. Viola, James E. Glassbrook, Jhansi R. Kalluri, Justin B. Hackett, Madison N. Wicker, Joshua Sternberg, Heather M. Gibson
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
The immune cytokine interleukin-12 (IL-12) is involved in cancer initiation and progression, autoimmunity, as well as graft versus host disease. The ability to monitor IL-12 via imaging may provide insight into various immune processes, including lev
Externí odkaz:
https://doaj.org/article/fde523f41fda4ae5ba7edd5c8a0575c7
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
Human cytomegalovirus (HCMV) is an important pathogen in developing fetuses, neonates, and individuals with compromised immune systems. Gaps in our understanding of the mechanisms required for virion assembly stand in the way of development of antivi
Externí odkaz:
https://doaj.org/article/555cd9c04aad4d3b837f3bb9554694ba
Autor:
James E. Glassbrook, Justin B. Hackett, Maria C. Muñiz, Madeline Bross, Greg Dyson, Nasrin Movahhedin, Alexander Ullrich, Heather M. Gibson
Publikováno v:
bioRxiv
BackgroundAntitumor antibody, or targeted immunotherapy, has revolutionized cancer treatment and markedly improved patient outcomes. A prime example is the monoclonal antibody (mAb) trastuzumab, which targets human epidermal growth factor receptor 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::177febf2606647f11f669a9b356b206e
https://europepmc.org/articles/PMC10197614/
https://europepmc.org/articles/PMC10197614/
Autor:
Namir Khalasawi, Zheng Dong, Congcong Yin, Xiaojun Wu, Qijun Yi, Frederic Geissmann, Qing-Sheng Mi, Li Zhou, James E. Glassbrook, Indra Adrianto, Queping Liu, Yi Yao
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications
Nature Communications
Alveolar macrophages (AMs) derived from embryonic precursors seed the lung before birth and self-maintain locally throughout adulthood, but are regenerated by bone marrow (BM) under stress conditions. However, the regulation of AM development and mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3787f875fd3a05f146cd31366484ed8
https://doaj.org/article/829edd029a0441149d3d80b09360dc22
https://doaj.org/article/829edd029a0441149d3d80b09360dc22
Autor:
Lisa Polin, Manohar Ratnam, Gregory Dyson, Donald J. DeGracia, Allison V. Mitchell, C. James Block, Guojun Wu, Douglas B. Craig, Heather M. Gibson, Ling Wu, Wei Chen, James E. Glassbrook
Publikováno v:
Oncogene
The epithelial-to-mesenchymal transition (EMT) has been recognized as a driving force for tumor progression in breast cancer. Recently, our group identified the RNA Binding Motif Single Stranded Interacting Protein 3 (RBMS3) to be significantly assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3a5f51e0bcc14547558bbaa21ffa82c
https://europepmc.org/articles/PMC9421946/
https://europepmc.org/articles/PMC9421946/
Autor:
Justin Hackett, Nasrin Movaheddin, James E Glassbrook, Madeline Bross, Maria Muñiz, Gregory Dyson, Heather Gibson
Publikováno v:
The Journal of Immunology. 208:66.08-66.08
Immune checkpoint inhibitors (ICI) for cancer therapy have improved outcomes for a variety of malignancies, however many patients fail to benefit. While tumor-intrinsic mechanisms are involved in therapy resistance, it is unclear to what extent host
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45cc481030cb985c810b11bc66a811e7
https://doi.org/10.4049/jimmunol.208.supp.66.08
https://doi.org/10.4049/jimmunol.208.supp.66.08
Publikováno v:
Cancer Immunology Research. 10:P055-P055
IL-12 is an attractive target for imaging active antitumor immunity, inflammation, and infection due to its function in innate and adaptive immune signaling. It has been widely reported to be involved in cancer initiation and progression, autoimmunit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12ab28bd29a0dde1a5de100c50f38fb1
https://doi.org/10.1158/2326-6074.tumimm21-p055
https://doi.org/10.1158/2326-6074.tumimm21-p055
Autor:
James E Glassbrook, Claire McCarthy, Justin Hackett, Maria Muñiz, Greg Dyson, Jennifer McCasland, Heather Gibson
Publikováno v:
The Journal of Immunology. 204:242.25-242.25
Monoclonal antibody (mAb) therapies have greatly improved outcomes for many cancer subtypes, many of which target tumor-associated antigens (TAA). Trastuzumab targets the TAA human epidermal growth factor 2 (HER2), inducing antibody dependent cellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49069f61f6743627a3074349139f453
https://doi.org/10.4049/jimmunol.204.supp.242.25
https://doi.org/10.4049/jimmunol.204.supp.242.25
Publikováno v:
Frontiers in Microbiology, Vol 9 (2018)
Frontiers in Microbiology
Frontiers in Microbiology
Human cytomegalovirus (HCMV) is an important pathogen in developing fetuses, neonates, and individuals with compromised immune systems. Gaps in our understanding of the mechanisms required for virion assembly stand in the way of development of antivi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6ae00540b0fa48ed8eed44a7da249c
https://www.frontiersin.org/article/10.3389/fmicb.2018.01888/full
https://www.frontiersin.org/article/10.3389/fmicb.2018.01888/full